|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
E-mail contact: weihong{at}interchange.ubc.ca
The amyloid β protein (Aβ) is derived from β-amyloid precursor protein (APP). Cleavage of APP by β-secretase generates a C-terminal fragment (APPCTFβ or C99), which is subsequently cleaved by γ-secretase to produce Aβ. BACE (or BACE1), the major β-secretase involved in cleaving APP, has been identified as a Type 1 membrane-associated aspartyl protease. In this study, we found that treatment with proteasome inhibitors resulted in an increase in APP C99 levels, suggesting that APP processing at the β-secretase site may be affected by the ubiquitin-proteasome pathway. To investigate whether the degradation of BACE is mediated by the proteasome pathway, cells stably transfected with BACE were treated with lactacystin. We found that BACE protein degradation was inhibited by lactacystin in a time- and dose-dependent manner. Non-proteasome protease inhibitors had no effect on BACE degradation. BACE protein is ubiquitinated. Furthermore, lactacystin increased APP C99 production and Aβ generation. Our data demonstrate that the degradation of BACE proteins and APP processing are regulated by the ubiquitin-proteasome pathway.
Key words: Alzheimer's Disease • APP • Aβ
This article has been cited by other articles:
![]() |
H. Liu, P. Wang, W. Song, and X. Sun Degradation of regulator of calcineurin 1 (RCAN1) is mediated by both chaperone-mediated autophagy and ubiquitin proteasome pathways FASEB J, October 1, 2009; 23(10): 3383 - 3392. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Qing, G. He, P. T. T. Ly, C. J. Fox, M. Staufenbiel, F. Cai, Z. Zhang, S. Wei, X. Sun, C.-H. Chen, et al. Valproic acid inhibits A{beta} production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models J. Exp. Med., November 24, 2008; 205(12): 2781 - 2789. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sipa, E. Sochacka, J. Kazmierczak-Baranska, M. Maszewska, M. Janicka, G. Nowak, and B. Nawrot Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA RNA, August 1, 2007; 13(8): 1301 - 1316. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhao, Y. Fu, M. Yasvoina, P. Shao, B. Hitt, T. O'Connor, S. Logan, E. Maus, M. Citron, R. Berry, et al. {beta}-Site Amyloid Precursor Protein Cleaving Enzyme 1 Levels Become Elevated in Neurons around Amyloid Plaques: Implications for Alzheimer's Disease Pathogenesis J. Neurosci., April 4, 2007; 27(14): 3639 - 3649. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Sun, Y. Tong, H. Qing, C.-H. Chen, and W. Song Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome FASEB J, July 1, 2006; 20(9): 1361 - 1368. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Sun, G. He, and W. Song BACE2, as a novel APP {theta}-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome FASEB J, July 1, 2006; 20(9): 1369 - 1376. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Zhou and W. Song Leaky Scanning and Reinitiation Regulate BACE1 Gene Expression Mol. Cell. Biol., May 1, 2006; 26(9): 3353 - 3364. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Li, W. Zhou, Y. Tong, G. He, and W. Song Control of APP processing and A{beta} generation level by BACE1 enzymatic activity and transcription FASEB J, February 1, 2006; 20(2): 285 - 292. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. H. Koh, C. A. F. von Arnim, B. T. Hyman, R. E. Tanzi, and G. Tesco BACE Is Degraded via the Lysosomal Pathway J. Biol. Chem., September 16, 2005; 280(37): 32499 - 32504. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Sun, Y. Wang, H. Qing, M. A. Christensen, Y. Liu, W. Zhou, Y. Tong, C. Xiao, Y. Huang, S. Zhang, et al. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes FASEB J, May 1, 2005; 19(7): 739 - 749. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |